Salvage lymphadenectomy or radiation therapy in prostate cancer patients with biochemical recurrence and PET positive lymph nodes after radical prostatectomy: a systematic review and pooled analysis
A partir d'une revue systématique de la littérature publiée jusqu'en juin 2023 (19 articles, 2 476 patients ; durée de suivi : au moins 12 mois), cette étude analyse les résultats après un traitement de sauvetage par radiothérapie ou par curage ganglionnaire chez des patients atteints d'un cancer de la prostate avec récidive biochimique et dont les résultats d'une tomographie par émission de positrons ont révélé un envahissement ganglionnaire
Objective: To analyze the oncologic outcomes of biochemical recurrence (BCR) patients who received salvage treatment of lymph node dissection (LND) or radiotherapy (RT) for positron emission tomography (PET)-positive lymph node recurrences following radical prostatectomy (RP). Methods: Research using the MEDLINE, Cochrane, and Web of Science databases was conducted until June 2023. Inclusion criteria were BCR patients that received salvage LND or RT for PET-positive lymph node recurrence following primary RP for prostate cancer. Studies with a follow-up period of less than 12 months were excluded. Results: This study included 2,476 patients (995 LND, 1481 RT) from 19 publications. The pooled incidences were 51.1% and 74.3% in PSA response, 69.8% and 26.9% in PSA progression, 41.5% and 26.9% in image progression, 41.5% and 32.0% in systemic progression, 0.9% and 0.5% in overall mortality, and 6.5% and 1.3% in cancer-specific mortality in LND and RT, respectively. Limitations include high heterogeneity. Conclusion: Although heterogeneity is high across all studies, the pooled rates of PSA, image, and systemic progressions are higher in LND than in RT concerning BCR patients with PET-positive lymph nodes. For future trial designs in BCR, assessing the optimal timing of PSMA PET scans, concurrent systemic therapy, and salvage therapy type is imperative.